ES2425314R1 - Composición farmacéutica combinada y uso para preparar medicamentos destinados al tratamiento de trastornos del sistema genitourinario - Google Patents

Composición farmacéutica combinada y uso para preparar medicamentos destinados al tratamiento de trastornos del sistema genitourinario Download PDF

Info

Publication number
ES2425314R1
ES2425314R1 ES201390004A ES201390004A ES2425314R1 ES 2425314 R1 ES2425314 R1 ES 2425314R1 ES 201390004 A ES201390004 A ES 201390004A ES 201390004 A ES201390004 A ES 201390004A ES 2425314 R1 ES2425314 R1 ES 2425314R1
Authority
ES
Spain
Prior art keywords
antibodies
activated
application
homeopathic
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES201390004A
Other languages
English (en)
Spanish (es)
Other versions
ES2425314A2 (es
Inventor
Oleg Iliich Epshtein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2010129294/15A external-priority patent/RU2542414C2/ru
Priority claimed from RU2010129295/15A external-priority patent/RU2531049C2/ru
Priority claimed from RU2011127053/15A external-priority patent/RU2565400C2/ru
Application filed by Individual filed Critical Individual
Publication of ES2425314A2 publication Critical patent/ES2425314A2/es
Publication of ES2425314R1 publication Critical patent/ES2425314R1/es
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES201390004A 2010-07-15 2011-07-15 Composición farmacéutica combinada y uso para preparar medicamentos destinados al tratamiento de trastornos del sistema genitourinario Pending ES2425314R1 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
RU2010129294/15A RU2542414C2 (ru) 2010-07-15 2010-07-15 Лекарственное средство для лечения эректильных дисфункций и способ лечения эректильных дисфункций
RU2010129294 2010-07-15
RU2010129295 2010-07-15
RU2010129295/15A RU2531049C2 (ru) 2010-07-15 2010-07-15 Лекарственное средство для лечения заболеваний предстательной железы и способ лечения заболеваний предстательной железы
RU2011127053 2011-07-01
RU2011127053/15A RU2565400C2 (ru) 2011-07-01 2011-07-01 Лекарственное средство для лечения заболеваний мочеполовой системы и способ лечения заболеваний мочеполовой системы
PCT/IB2011/002417 WO2012007849A2 (en) 2010-07-15 2011-07-15 Combination pharmaceutical composition and methods of treating genitourinary system disorders

Publications (2)

Publication Number Publication Date
ES2425314A2 ES2425314A2 (es) 2013-10-14
ES2425314R1 true ES2425314R1 (es) 2014-07-09

Family

ID=44899158

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201390004A Pending ES2425314R1 (es) 2010-07-15 2011-07-15 Composición farmacéutica combinada y uso para preparar medicamentos destinados al tratamiento de trastornos del sistema genitourinario

Country Status (17)

Country Link
US (1) US20130064860A1 (https=)
EP (1) EP2593483A2 (https=)
JP (3) JP2013538791A (https=)
CN (1) CN103282384A (https=)
AU (1) AU2011278042B2 (https=)
CA (1) CA2805094A1 (https=)
DE (1) DE112011102350T5 (https=)
EA (1) EA029860B1 (https=)
ES (1) ES2425314R1 (https=)
FR (1) FR2962655A1 (https=)
GB (1) GB2495885B (https=)
IT (1) ITTO20110631A1 (https=)
MX (1) MX354187B (https=)
MY (1) MY165267A (https=)
NZ (1) NZ606775A (https=)
SG (2) SG187036A1 (https=)
WO (1) WO2012007849A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
PH12013500107A1 (en) 2010-07-15 2013-03-11 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
EP2593474A2 (en) 2010-07-15 2013-05-22 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
EA029199B1 (ru) 2010-07-21 2018-02-28 Олег Ильич Эпштейн Комбинированная фармацевтическая композиция для лечения синдрома дефицита внимания и гиперактивности и способы лечения синдрома дефицита внимания и гиперактивности
PH12013500142A1 (en) 2010-07-21 2013-03-11 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
CA2926183C (en) * 2013-10-23 2018-07-03 Gemvax & Kael Co., Ltd. Composition for treating and preventing benign prostatic hyperplasia
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1547612A1 (en) * 2002-08-02 2005-06-29 Oleg Iliich Epshtein Medicinal agent and method for curing erectile dysfunction
EP1547611A1 (en) * 2002-08-02 2005-06-29 Oleg Iliich Epshtein Medicinal agent and method for curing prostate diseases
US20100166762A1 (en) * 2000-06-20 2010-07-01 Oleg Iliich Epshtein Method of treating a pathological syndrome

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
RU2197266C1 (ru) * 2001-06-01 2003-01-27 Эпштейн Олег Ильич Лекарственное средство и способ лечения эрозивных и воспалительных заболеваний желудочно-кишечного тракта
RU2001134982A (ru) * 2001-12-26 2004-02-20 Олег Ильич Эпштейн Способ коррекции иммунного ответа и лекарственное средство
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
CA2518965C (en) 2003-03-14 2018-10-30 Nutrition Research Inc. Homeopathic formulations useful for treating pain and/or inflammmation
ATE532416T1 (de) * 2004-09-03 2011-11-15 Chr Hansen As Fermentierte milchproteine mit rezeptor-ligand und ihre verwendungen
AU2006341342B2 (en) * 2006-04-04 2010-05-20 Dong-A Pharmaceutical.Co., Ltd. Agent for the prevention and treatment of prostatic hyperplasia comprising pyrazolopyrimidinone compound
RU2438707C2 (ru) * 2006-06-06 2012-01-10 Олег Ильич Эпштейн Лекарственное средство для перорального лечения сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе, и способ получения твердой лекарственной формы для пероральной терапии сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе
BRPI0712540A2 (pt) * 2006-06-06 2012-10-16 Oleg Iliich Epshtein agente medicinal para tratar adiposidade, diabetes, e doenças associadas com intoleráncia a glicose
EP2040756A4 (en) * 2006-07-13 2013-01-09 Mazence Inc COMPOSITION CONTAINING ACIDIC AMINO ACID CHELATE AND METAL ACCELERATING METAL ABSORPTION
JP2013532181A (ja) * 2010-07-15 2013-08-15 イリイチ・エプシテイン オレグ 組み合わせ医薬組成物及び胃腸管の機能的な疾患又は状態を治療する方法
PH12013500107A1 (en) * 2010-07-15 2013-03-11 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
EP2593477A2 (en) * 2010-07-15 2013-05-22 Oleg Iliich Epshtein Pharmaceutical compositions and methods of treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100166762A1 (en) * 2000-06-20 2010-07-01 Oleg Iliich Epshtein Method of treating a pathological syndrome
EP1547612A1 (en) * 2002-08-02 2005-06-29 Oleg Iliich Epshtein Medicinal agent and method for curing erectile dysfunction
EP1547611A1 (en) * 2002-08-02 2005-06-29 Oleg Iliich Epshtein Medicinal agent and method for curing prostate diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Jonas W. B. et al. A critical overview of homeopathy. Ann. Intern. Med. 2003, Vol. 138, páginas 393-399 (todo el documento) *
Shang A. et al. Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy. The Lancet. 27.08.2005, Vol. 366, páginas 726-732 (todo el documento) *
Vickers A. J. et al. Clinical Trials of Homeopathy and Placebo: Analysis of a Scientific Debate. The Journal of Alternative and Complementary Medicine. 2000, Vol. 6, Nº 1, páginas 49-56 (todo el documento) *

Also Published As

Publication number Publication date
EP2593483A2 (en) 2013-05-22
ITTO20110631A1 (it) 2012-01-16
SG187036A1 (en) 2013-02-28
WO2012007849A2 (en) 2012-01-19
ES2425314A2 (es) 2013-10-14
DE112011102350T5 (de) 2013-04-18
JP2018150322A (ja) 2018-09-27
MY165267A (en) 2018-03-15
GB2495885A (en) 2013-04-24
JP2016199570A (ja) 2016-12-01
EA201300129A1 (ru) 2013-12-30
MX354187B (es) 2018-02-16
SG10201505564VA (en) 2015-09-29
NZ606775A (en) 2015-08-28
GB201302651D0 (en) 2013-04-03
CA2805094A1 (en) 2012-01-19
WO2012007849A3 (en) 2012-04-05
GB2495885B (en) 2017-11-22
US20130064860A1 (en) 2013-03-14
AU2011278042B2 (en) 2017-02-16
EA029860B1 (ru) 2018-05-31
FR2962655A1 (fr) 2012-01-20
MX2013000547A (es) 2014-04-14
JP2013538791A (ja) 2013-10-17
AU2011278042A1 (en) 2013-03-07
CN103282384A (zh) 2013-09-04

Similar Documents

Publication Publication Date Title
ES2425314R1 (es) Composición farmacéutica combinada y uso para preparar medicamentos destinados al tratamiento de trastornos del sistema genitourinario
ES2425004R1 (es) Composición farmacéutica combinada y su uso para prerarar un medicamento destinado al tratamiento de las enfermedades o condiciones funcionales del tracto gastrointestinal
Nelly et al. Plants used as remedies antirheumatic and antineuralgic in the traditional medicine of Lebanon
Et-tahir Ethnopharmacological survey of aromatic and medicinal plants of the pharmacopoeia of northern Morocco
GT199900203A (es) Composiciones de celecoxib.
AR073123A1 (es) Composicion farmaceutica que comprende un taxano sustancialmente amorfo para utilizarse en el tratamiento de la enfermedad neoplasica
PY1128718A (es) Formulaciones estabilizadas que contienen anticuerpos anti- ngf
EA201490654A1 (ru) Новые ингибиторы вирусной репликации
AR062511A1 (es) Formas de dosificacion farmaceutica
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
EA200700362A1 (ru) Конъюгат, содержащий антивирусное соединение, в частности ингибирующее вич, фармацевтическая композиция и набор стандартной дозы лекарственного препарата на его основе, способ ингибирования с его помощью
AR047928A1 (es) Derivados de tetrahidropiridoindol
MA35748B1 (fr) Fluorométhyl-5,6-dihydro-4h-[1,3]oxazines
EA200501203A1 (ru) Жидкие фармацевтические композиции палоносетрона
EA200802020A1 (ru) Тетрагидропиримидоазепины и их применение в качестве модуляторов trpv 1
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
UY28702A1 (es) Derivados de quinazolina
FI20095600A7 (fi) Koostumus ihosairauksien hoitoa varten
CO5200850A1 (es) Composicion farmaceutica para profilaxis y tratamiento de sintomas asociados con la gripa, influenza y enfermedades similares y procedimiento para su aplicacion
EA201490417A1 (ru) Новые легкоразрушающиеся ингибиторы pde 4
DE602006016785D1 (de) Orale pharmazeutische zusammensetzung zur behandlung einer cox-2-vermittelten erkrankung
MX2015007091A (es) Formulacion liquida oralmente administrada.
ES2351006B1 (es) Composicion cosmetica caracterizada por contener al menos una esencia floral junto a al menos, un aceite esencial
Navaei et al. Study on the phytochemical constituents of Thymus kotschyanus Boiss. Et Hohen and its efficacy on the symptoms’ improvement of irritant bowel syndrome
ES2441917R1 (es) Composición farmacéutica para uso en inflamación y dolor

Legal Events

Date Code Title Description
FC2A Grant refused

Effective date: 20170828